Table S1.
The patient profiles of HCC samples for RNA-sequencing
| Characteristics | Portal vein invasion (n=3) | Without portal vein invasion (n=3) |
|---|---|---|
| Gender | ||
| Male | 2 | 2 |
| Female | 1 | 1 |
| Age (years) | ||
| ≤60 | 3 | 3 |
| >60 | 0 | 0 |
| HCC history | ||
| Negative | 3 | 3 |
| Positive | 0 | 0 |
| HBsAg | ||
| Negative | 0 | 1 |
| Positive | 3 | 2 |
| Anti-HCV | ||
| Negative | 3 | 3 |
| Positive | 0 | 0 |
| AFP | ||
| ≥400 ng/mL | 3 | 3 |
| <400 ng/mL | 0 | 0 |
| Child-Pugh classification | ||
| Child-Pugh A | 1 | 1 |
| Child-Pugh B | 2 | 2 |
| Tumor diameter | ||
| ≥5 cm | 2 | 2 |
| <5 cm | 1 | 1 |
| TNM | ||
| I/II | 1 | 1 |
| III/IV | 2 | 2 |
| Differentiation | ||
| High/moderate | 1 | 2 |
| Low | 2 | 1 |
| BCLC stage | ||
| Stage A | 0 | 0 |
| Stage B | 0 | 2 |
| Stage C | 3 | 1 |
Abbreviations: HCC, hepatocellular carcinoma; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; BCLC, Barcelona clinic liver cancer; AFP, alpha-fetoprotien.